Republicans consider a new attack on Biden ‘march-in’ plan for lower drug prices; Startup Alumis raises $259 million as it prepares for psoriasis trial

Taking stock of the drug industry, from the lab to the medicine chest

March 6, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kevin Dietsch/Getty Images STAT+ | Republicans consider a new attack on Biden 'march-in' plan for lower drug prices Biden has taken aim at drug patents. Republicans are in the early stage of undermining that plan with a technical maneuver. By John Wilkerson STAT+ | Startup Alumis raises $259 million as it prepares for psoriasis trial The company's oral medicine is designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. By Allison DeAngelis STAT+ | Oracle Health chair says Cerner isn't competing with Epic Cerner's new owner aims to win customers with cloud services instead of just electronic health records, Oracle Health's chair tells STAT.  By Mohana Ravindranath

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser